Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...

Relacorilant plus nab-paclitaxel could be a new standard of care for platinum-resistant ovarian cancer, according to Alexander Olawaiye, MD.

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

In March 2024, Lantern dosed two subjects in a Phase Ia/Ib trial of LP-284 for relapsed or refractory non-Hodgkin’s lymphoma ...

The COMPASSION-16 trial by Xiaohua Wu and colleagues addresses a crucial need in the management of advanced cervical cancer by evaluating cadonilimab, a novel bispecific antibody targeting PD-1 and ...

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in ...

Leishmaniasis is a parasitic disease that affects up to 1 million people worldwide each year. It is caused by the protozoan ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Panelists discuss how the unprecedented 5-year progression-free survival benefit (60% vs 8%) demonstrated in the CROWN trial ...

In a world of quick wins and impatient headlines, Martin Goebel is playing the long game. Now Director for Mexico at ...